ESPE Yearbook of Paediatric Endocrinology

Brief Summary: This single-center, retrospective cohort study compared the final adult height (FAH) of 92 male childhood cancer survivors (CCS) with growth hormone deficiency GHD) treated with growth hormone alone (monotherapy) or in combination with an aromatase inhibitor. The addition of AI to GH therapy did not improve FAH.This study from the Children’s Hospital of Philadelphia is the most extensive study on the role of AI associated with GH in i...

Brief summary: This open-label extension trial enrolled all subjects completing the two previous phase 3 Lonapegsomatropin trials, heiGHt and fliGHt. The results confirm the efficacy of this LAGH formulation in improving height SDS, without major adverse events.Lonapegsomatropin is a long-acting GH consisting of 3 components: unmodified human GH (hGH), an inert glycol carrier, and a TransCon linker that transiently binds the other 2 components. The glyco...